Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11254006 | 0.83 | CSNK1A1 (0.32) | CSNK1A1CLK4KHK | |
| SCHEMBL1388593 | 0.77 | — | — | |
| SCHEMBL8882232 | 0.73 | KHK (0.37) | TRPV4KHK | |
| SCHEMBL27959747 | 0.68 | ALDH1A1 (0.33) | — | |
| SCHEMBL29421236 | 0.68 | GPR35 (0.41) | CSNK1A1CLK4TRPV4KHK | |
| SCHEMBL2435542 | 0.68 | CYP3A4 (0.56) | CSNK1A1CLK4TRPV4KHK | |
| SCHEMBL165074 | 0.68 | GPR35 (0.41) | CSNK1A1CLK4TRPV4KHK | |
| SCHEMBL989338 | 0.68 | DYRK1A (0.44) | CSNK1A1CLK4TRPV4 | |
| SCHEMBL5660087 | 0.67 | — | — | |
| SCHEMBL443970 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | claimed |
| CN-1471515-A | Compounds effective as beta-2-adrenoreceptor agonists as well as PDE-4-inhibitors | ��̹��ҽҩ��˾ | 2004-01-28 | — | — | CN | claimed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | claimed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | claimed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | claimed |
| EP-0664788-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | Byk Nederland BV (NL) | 1995-08-02 | — | — | EP | claimed |
| WO-1994008945-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | BYK NEDERLAND BV (NL) | 1994-04-28 | — | — | WO | claimed |
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| CN-1471515-A | Compounds effective as beta-2-adrenoreceptor agonists as well as PDE-4-inhibitors | ��̹��ҽҩ��˾ | 2004-01-28 | — | — | CN | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | disclosed |
| US-5599966-A | SUITABLE FOR TREATMENT OF DISEASES OF RESPIRATORY PASSAGES | BYK NEDERLAND BV (NL) | 1997-02-04 | — | — | US | disclosed |
| EP-0664788-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | Byk Nederland BV (NL) | 1995-08-02 | — | — | EP | disclosed |
| WO-1994008945-A1 | SUBSTITUTED ETHANOLAMINE ESTERS | BYK NEDERLAND BV (NL) | 1994-04-28 | — | — | WO | disclosed |
| EP-0049728-A2 | Method for enhancing the growth rate of meat-producing animals and for improving the lean meat to fat ratio thereof | AMERICAN CYANAMID COMPANY (US) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | CSNK1A1 384/4885CLK4 4016/4885TRPV4 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.